Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 355

1.

Data for drugs available through low-cost prescription drug programs are available through pharmacy benefit manager and claims data.

Zhu VJ, Belsito A, Tu W, Overhage JM.

BMC Clin Pharmacol. 2012 Jun 22;12:12. doi: 10.1186/1472-6904-12-12.

2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.

Utilization and Costs of Compounded Medications for Commercially Insured Patients, 2012-2013.

McPherson T, Fontane P, Iyengar R, Henderson R.

J Manag Care Spec Pharm. 2016 Feb;22(2):172-81. doi: 10.18553/jmcp.2016.22.2.172.

4.

Impact of type 2 diabetes mellitus on prescription medication burden and out-of-pocket healthcare expenses.

Rodbard HW, Green AJ, Fox KM, Grandy S; SHIELD Study Group.

Diabetes Res Clin Pract. 2010 Mar;87(3):360-5. doi: 10.1016/j.diabres.2009.11.021. Epub 2010 Jan 4.

PMID:
20047768
5.

A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.

Clark BE, Siracuse MV, Garis RI.

Res Social Adm Pharm. 2009 Jun;5(2):133-42. doi: 10.1016/j.sapharm.2008.06.002. Epub 2009 Jan 31.

PMID:
19524861
6.

Impact of cost sharing on prescription drugs used by Medicare beneficiaries.

Goedken AM, Urmie JM, Farris KB, Doucette WR.

Res Social Adm Pharm. 2010 Jun;6(2):100-9. doi: 10.1016/j.sapharm.2010.03.003. Epub 2010 May 7.

PMID:
20511109
7.

A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.

Misurski D, Lage MJ, Fabunmi R, Boye KS.

Appl Health Econ Health Policy. 2009;7(4):245-54. doi: 10.2165/11318730-000000000-00000.

PMID:
19905038
8.

Utilization of oral hypoglycemic agents in a drug-insured U.S. population.

Boccuzzi SJ, Wogen J, Fox J, Sung JC, Shah AB, Kim J.

Diabetes Care. 2001 Aug;24(8):1411-5.

PMID:
11473078
9.

Assessing changes in third-party gross margin for a single community pharmacy.

Urick BY, Urmie JM, Doucette WR, McDonough RP.

J Am Pharm Assoc (2003). 2014 Jan-Feb;54(1):27-34. doi: 10.1331/JAPhA.2014.13083.

PMID:
24362541
10.

Impact of pharmacy benefit design on prescription drug utilization: a fixed effects analysis of plan sponsor data.

Roebuck MC, Liberman JN.

Health Serv Res. 2009 Jun;44(3):988-1009. doi: 10.1111/j.1475-6773.2008.00943.x. Epub 2009 Jan 28.

11.

Diabetes prevalence and hospital and pharmacy use in the Veterans Health Administration (1994). Use of an ambulatory care pharmacy-derived database.

Pogach LM, Hawley G, Weinstock R, Sawin C, Schiebe H, Cutler F, Zieve F, Bates M, Repke D.

Diabetes Care. 1998 Mar;21(3):368-73.

PMID:
9540017
12.

Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods.

Tunceli O, Wade R, Gu T, Bouchard JR, Aagren M, Luo W.

Curr Med Res Opin. 2010 Aug;26(8):1827-34. doi: 10.1185/03007995.2010.488544.

PMID:
20491613
13.

A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.

Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B.

Clin Ther. 2009 Mar;31(3):623-31. doi: 10.1016/j.clinthera.2009.03.005.

PMID:
19393853
14.

Patterns of use and expenses associated with mail-service pharmacy in adults with diabetes.

Wu J, Davis-Ajami ML, Noxon V.

J Am Pharm Assoc (2003). 2015 Jan-Feb;55(1):41-51. doi: 10.1331/JAPhA.2015.14058.

PMID:
25539092
15.

Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.

Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME.

Appl Health Econ Health Policy. 2008;6(2-3):103-12. doi: 10.2165/00148365-200806020-00003.

PMID:
19231904
16.
17.

Diabetes pharmacy management: balancing safety, cost, and outcomes.

Dunn JD.

Am J Manag Care. 2010 Aug;16(7 Suppl):S201-6.

18.

Drug utilization and cost in a Medicaid population: a simulation study of community vs. mail order pharmacy.

Valluri S, Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL.

BMC Health Serv Res. 2007 Jul 30;7:122.

19.

Cluster analysis of state Medicaid prescription drug benefit programs based on potential determinants of per capita drug expenditure.

Roy S, Madhavan SS.

Res Social Adm Pharm. 2009 Mar;5(1):51-62. doi: 10.1016/j.sapharm.2008.05.001.

PMID:
19285289
20.

Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.

Cooke CE, Lee HY, Tong YP, Haines ST.

Curr Med Res Opin. 2010 Jan;26(1):231-8. doi: 10.1185/03007990903421994.

PMID:
19921965

Supplemental Content

Support Center